Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA exon editing could be the right platform for this area of medicine, and why he thinks Roche is the right partner.
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
.png){kind=logo}
